Back to search

University of Crete (UOC)

Investigation of the role of p110δ PI3K and RhoA in cancer and metastasis in in vivo mouse models

Abstract

dc:description

Phosphoinositide-3 kinase delta (PI3Kδ) is an isoform of class I PI3Ks, composed of the catalytic p110δ subunit and one of five regulatory p85 subunits. While primarily studied in immune cells, PI3Kδ has also been implicated in cancer progression. On the other hand, PTEN is a tumor suppressor that negatively regulates PI3K-Akt signaling, preventing uncontrolled cell proliferation and survival. The loss or inactivation of PTEN is frequently observed in cancer, leading to hyperactivation of the PI3K pathway and promoting tumorigenesis. This PhD thesis aims on one hand to elucidate the mechanisms linking PI3Kδ with PTEN in cancers expressing high p110δ levels, such as breast cancer and on the other, to investigate whether PI3Kδ inhibition, either as monotherapy or in combination with other treatments, holds therapeutic potential in cancers expressing low p110δ levels, such as skin cancer. To address these research objectives, the current PhD thesis has been divided into three main parts. In the first part, we investigated the mechanisms by which PTEN is activated following PI3Kδ inhibition, with a specific focus on identifying the tyrosine kinase responsible for PTEN tyrosine phosphorylation downstream of the RhoA/ROCK pathway. We demonstrated that focal adhesion kinase (FAK) phosphorylates PTEN, and we identified Tyr336 on PTEN as the phosphorylation site targeted by FAK. This phosphorylation event enhanced PTEN’s phosphatase activity, protein–lipid interactions, and overall protein stability. Furthermore, in high p110δ-expressing cells, such as macrophages and breast cancer cell lines, we found that FAK phosphorylation/activity is negatively regulated by PI3Kδ, while is positively regulated by RhoA-associated kinase (ROCK). Indeed, FAK phosphorylation was increased in these cells upon p110δ inhibition, whereas pharmacologic inhibition of RhoA/ROCK restored FAK phosphorylation levels back to normal levels. Similarly, inhibition of FAK reduced PTEN phosphorylation and restored the functional defects associated with p110δ inactivation, including the increased Akt phosphorylation and cell proliferation. Conclusively, this work identifies FAK as a target of PI3Kδ that links RhoA with PTEN and establishes for the first time that PTEN is a substrate of FAK-mediated Tyrosine phosphorylation.In the second part, we investigated the association between PI3Kδ and PTEN in breast cancer progression. Although no mutations in the p110δ subunit have been detected in breast cancer, we found that p110δ expression gradually increases, while PTEN activity progressively declines during breast tumor progression in mice. Moreover, pharmacological inactivation of p110δ in mice effectively halted breast tumor growth, with this effect to be mechanistically linked to the restoration and enhancement of PTEN activity in tumor cells. These findings highlight the potential of p110δ inhibition as a therapeutic strategy for breast cancer by restoring PTEN function. In the third part, we explored whether a combination treatment consisting of the selective inhibition of PI3Kδ in macrophages alongside with local inhibition of p190RhoGAP in cancer cells could impact growth and metastasis of tumors lacking or expressing low p110δ, such as skin cancers, including malignant melanoma and cutaneous squamous cell carcinoma (cSCC), which typically exhibit low p110δ expression, making them ideal models for studying alternative therapeutic strategies beyond single PI3Kδ inhibition. Moreover, given that macrophages play a key role in the tumor microenvironment (TME) and often promote cancer progression, while p110δ is highly expressed in immune cells, including macrophages, its inhibition has the potential to impair macrophage functions. Meanwhile, p190RhoGAP suppresses RhoA/ROCK pathway, influencing tumor cell migration and metastasis. Importantly, by downregulating RhoA/ROCK, p190RhoGAP may also promote tumor progression by suppressing PTEN’s tumor-suppressor activity. Indeed, our findings demonstrate that melanoma and cSCC progression can be effectively blocked by the combined inhibition of PI3Kδ in macrophages and p190RhoGAP in tumor cells. Specifically, we found that targeted deletion of p190RhoGAP in tumor cells, combined with the adoptive transfer of macrophages from δD910A/D910A mice into tumor-bearing mice, significantly abrogated melanoma and SCC progression, by simultaneously activating RhoA and PTEN in tumor cells and reducing the accumulation of tumor-associated macrophages (TAMs) within the tumors. Notably, the effectiveness of this combined treatment was consistent across melanoma tumors lacking activating BRAF mutations and those harboring the common BRAF(V600E) mutation. Additionally, the efficiency if this therapy was associated with decreased autotaxin (ATX) expression in tumor cells and the surrounding stroma, effectively bypassing the positive feedback loop of ATX expression observed with direct pharmacological ATX inhibition. Together, these findings underscore the importance of targeting both cancer cells and macrophages in skin cancer therapy and reveal a previously unrecognized reverse link between ATX and RhoA, highlighting further the therapeutic potential of p110δ inhibition as part of a combinatorial regimen for treating skin cancers.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tzenaki, Niki
  • Τζενάκη, Νίκη

Subjects

dc:subject × 20

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60231

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tzenaki, Niki; Τζενάκη, Νίκη. Investigation of the role of p110δ PI3K and RhoA in cancer and metastasis in in vivo mouse models. University of Crete (UOC), 2025. http://hdl.handle.net/10442/hedi/60231